摘要
目的:研究卵泡雌激素(FSH)受体结合抑制剂(FRBI)对卵巢组织中FSH受体(FSHR)和雌激素受体β(ERβ)基因和蛋白表达水平的作用,并探究FRBI是否通过调控FSHR和ERβ的表达来抑制卵巢癌的发生.方法:将180只雌性小鼠随机分为对照组(CG)、FSH组和实验组.实验组又分为4个小组(n=30),分别注射不同浓度的FRBI(10 mg/kg至40 mg/kg),测定卵巢皮质厚度(OCT)、次级卵泡的最大横径(MTD)、FSHR mRNA的表达水平和血清雌二醇(E2)浓度.结果:FRBI可以减少OCT和卵泡数量.较高剂量的FRBI(30 mg/kg~40 mg/kg)可抑制卵巢和卵泡发育,降低卵巢内ERβ和FSHR mRNA蛋白的表达水平,并减少E2产生.结论:FRBI可下调卵巢组织FSHR和ERβ表达水平.
Objective To investigate the effects of FSH receptor binding inhibitor(FRBI) on the expression of FSH receptor and estrogen receptor β(ERβ) gene and protein in mouse ovary, and to explore the role of FRBI in ovary, as well as whether to suppress ovarian cancer by down-regulating the expression levels of FSHR and ERβ.Methods Mice were randomly divided into control group(CG),experimental group and FSH(n=30).The experimental group was injected with different concentrations of FRBI,and the ovarian cortical thickness(OCT),the maximum transverse diameter of the secondary follicle(MTD),the expression of FSHR mRNA and the concentration of estradiol(E2) were compared.Results FRBI can reduce the number of OCT and follicles.High doses of FRBI(30 mg/kg~40 mg/kg) inhibited ovarian and follicular development, attenuated ERβ and FSHR mRNA and protein expression in the ovary, and inhibited E2 production.The results indicated that FRBI inhibits the overexpression of FSHR in ovarian tissue.Conclusion FRBI may be used to inhibit cancerous ovarian cancer.
作者
巩转娣
袁肇方
牛宇辉
张向博
魏锁成
GONG Zhuan-di;YUAN Zhao-fang;NIU Yu-hui;ZHANG Xiang-bo;WEI Suo-cheng(Hospital of Northwest Minzu University,Lanzhou 730030,China;Life Science and Engineering College,Northwest Minzu University,Lanzhou 730030,China;Biomedicine Research Center,Northwest Minzu University,Lanzhou 730030,China)
出处
《西北民族大学学报（自然科学版）》
2021年第3期43-49,共7页
Journal of Northwest Minzu University(Natural Science)
基金
国家自然科学基金项目(31460684)
西北民族大学高原动物疾病创新团队项目(2020-88-07-3)。
关键词
卵巢癌
促卵泡激素
FSH受体结合抑制剂
雌激素受体
表达水平
Ovarian cancer
Follicle stimulating hormone
FSH receptor binding inhibitor
Estrogen receptor
Expression
